PhotoPharmics said that enrollment in its Light for PD randomized, double-blind, placebo-controlled trial has exceeded its initial goal of 300 participants. The company said that new clinical sites have been opened in Illinois, Florida, and Arizona, expanding access across a total of 19 states.
According to the company, the trial remains open to participants nationwide. The Light for PD study evaluates Celeste, an investigational FDA Breakthrough non-invasive light therapy designed to improve both motor and non-motor symptoms of Parkinson’s disease. PhotoPharmics said that participants use the device at home, typically during daily activities, without needing to alter their existing medication regimens.
The company claims that Celeste works by delivering specific wavelengths of light to the eyes to restore circadian rhythms and support brain function—an approach aimed at improving alertness, sleep, mood, and core PD symptoms.
According to the company, the enrollment milestone marks what is now the largest study of its kind, reflecting both the scientific promise of the therapy and increasing patient demand for non-drug treatment options.
